Targeted Treatment of #mCRPC Based on Genetic Profiling: Results from the BARCODE2 Trial. Presented by Dr. Ann-Britt Jones, #ESMO26 written coverage by @zklaassen_md &gt; https://b

UroToday.com· @urotoday · X·2026-10-24 02:45· 2 天前评分70

正文 · 原文

Targeted Treatment of #mCRPC Based on Genetic Profiling: Results from the BARCODE2 Trial. Presented by Dr. Ann-Britt Jones, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/47B7thq #ProstateCancer #PrecisionOncology @myESMO

362 浏览 · 3 赞 · 3 转发 · 1 回复

会议摘要

2218RONCT04746300按 Rapid oral: Genitourinary tumours, prostate, penile and testis 对上

Distinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)

https://esmocongress.esmo.org

2220RONCT04746300按 Rapid oral: Genitourinary tumours, prostate, penile and testis 对上

Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)

https://esmocongress.esmo.org

帖内回复

sciqst@sciqst
@urotoday @zklaassen_md @myESMO The key distinction is prognostic versus predictive value: a genomic signal may correlate with outcomes without showing which treatment will work best. Explore that broader evidence with a biomedical literature review at https://sciqst.com.

来源：UroToday.com · x.com